Presentation
Created in 2004 by two French doctors, Professor Bruno Dubois, a neurologist specialising in Alzheimer's disease, and Doctor Olivier de Ladoucette, a gerontological psychiatrist, the Alzheimer's Research Foundation is located at the heart of the Pitié-Salpêtrière Hospital Group, close to clinical research. The State recognised the public utility of its action in 2016.
Our vision
With the mobilization of all, our generation can knock out Alzheimer's!
Alzheimer's disease is a major public health issue, affecting an ever-increasing number of people in France and around the world.
Scientific research has made it possible to identify the lesions responsible for the disease and to understand how they develop.
The global challenge now is to provide reliable diagnostics and develop effective treatments.
Only research will enable us to achieve this objective rapidly.
We are convinced that the mobilization of all players in society - public authorities, researchers, associations, individuals and patients - will enable us to defeat the disease. Within 10 years, it is possible to achieve significant results in stopping the disease.
Our mission
The Alzheimer's Research Foundation is giving new impetus to research into the disease. It funds projects that combine innovation and scientific excellence, led by researchers from all over the world. It focuses on clinical research to improve diagnosis and pave the way for effective treatments. It mobilises and federates specialists in several disciplines and involves patients in research protocols. It structures its action around a state-of-the-art research centre at the Pitié Salpêtrière Hospital on Alzheimer's disease and neurodegenerative diseases. By mobilising the general public and partners, it raises funds to finance research and contributes to accelerating discoveries.
Our values
The Foundation's values are humanism in its approach to research, innovation, scientific excellence and boldness.
Call for projects 2021
The Alzheimer's Research Foundation (ARF) is launching a call for proposals to support research into the pathophysiological mechanisms, diagnostic markers and therapeutic approach of Alzheimer's disease and related disorders.
Deadline for receipt of completed form: March 17, 2021. Download here
BACKGROUND
Neurodegenerative diseases and age-related illnesses are becoming increasingly important. At the same time, neuroscience is booming. The Alzheimer's Research Foundation (ARF) supports any research likely to facilitate and accelerate the discovery of new therapeutic approaches for Alzheimer's disease (AD), and more specifically along four main lines of research:
- Identification of sensitive and specific biomarkers
- Structural and functional brain imaging
- Megadata management and development of decision-making algorithms
- Pre-clinical and clinical "proof-of-concept" studies
WHO CAN SUBMIT A PROJECT?
The FRA gives priority to projects whose operators are researchers who have demonstrated their interest and specific competence in translational or clinical research in the areas chosen by the FRA (see context above). They must belong to a recognized institution in the field, and may apply collectively or as an institution.
Please note: One or more PhD or post-doc contracts can be supported through team projects. They must be supervised by a PI working at a French university or research institute. However, the financial support provided by the Foundation must not be used to remunerate the PI.
WHICH PROJECTS CAN BE SUPPORTED BY THE FOUNDATION?
A pre-selection of projects will be carried out by the FRA on the basis of a letter of intent and a questionnaire available on the Foundation's website, which will enable the FRA to assess whether the theme of the project is in line with the Foundation's objectives, and whether it complements projects it has previously funded (prizes, scholarships, grants).
Shortlisted projects and their promoters will then be required to complete a full application for research funding by the deadline set (the completed application will be sent to shortlisted applicants)
Final application deadline: June 1, 2021.
Each complete application will be reviewed and evaluated by two randomly selected members of the FRA's International Scientific Advisory Board who will be the project's rapporteur and co-rapporteur. The evaluation of the applications will focus on the experience of the applicant through his/her titles and work and that of his/her team, the scientific value of the project, the rigour of its methodology and its feasibility. The rapporteur and co-rapporteur may be joined by one or more specialists in the research area in which the project falls.
About 10 applications will be selected for voting by the International Scientific Committee of the FRA, which will rank them on the basis of the same criteria as the first selection by the rapporteur. The final number of applications selected will depend on the amount of budget required to carry out the corresponding projects.
WHAT ARE THE AMOUNTS ALLOCATED TO SELECTED PROJECTS?
The Alzheimer's Research Foundation allocates approximately €500,000 per year to selected projects.
These projects can be spread over several years if they demonstrate their extreme relevance in the field of Alzheimer's disease research.
Funding will be allocated from January 2, 2022.
Publications
All publications, book chapters or public presentations relating to the results of FRA-supported research must acknowledge this support.
Interruption of financing
The FRA reserves the right to discontinue its support at any time should the work carried out no longer correspond to the terms of the commitments made before the research was set up.
Financing review
Any request for a budget revision or an extension of the original duration of the research work must be made in writing to the FRA in good time.